Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG - 1 Feb 2014

Starz Hans, Gutschi Manuela, Welzel Julia, Haas Christian

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fatal Outcome
Share to Indoles
Share to Melanoma
Share to Proto-Oncogene Proteins B-raf

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Skin Neoplasms

Share to Sulfonamides

Share to Treatment Failure

Share to Vemurafenib

Source

Identifiers

PMID: 24238398
DOI: 10.1111/ddg.12231

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.PMID 24238398Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.Semantic proximity Read ↗

Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma.Semantic proximity Read ↗

Vemurafenib therapy for stage IV melanoma with V600G-mutation.Semantic proximity Read ↗

BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report.Semantic proximity Read ↗

Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.Semantic proximity Read ↗

Which drug, and when, for patients with BRAF-mutant melanoma?Semantic proximity Read ↗

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.Semantic proximity Read ↗

Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.Semantic proximity Read ↗

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.Semantic proximity Read ↗

Biology and Treatment of BRAF Mutant Metastatic MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.